Nucleic acids produced by biological methods for vaccine production

The present invention relates to a nucleic acid sequence produced by a biological method comprising two or three primary nucleic acid sequence portions of SARS-CoV-2 and no more than three secondary nucleic acid sequence portions wherein the secondary nucleic acid sequence portions encode an amino acid sequence having the function of the SARS-CoV-2 amino acid sequence encoded by ORF3a, ORF6, ORF7a or ORF8. The invention also relates to host cells or kits for producing the nucleic acids of the invention, vectors encoding the nucleic acids of the invention and products, such as viral envelopes, obtainable by expression of the nucleic acids of the invention. The invention also relates to a pharmaceutical composition comprising the nucleic acid of the invention or a derivative thereof, preferably for use in the prevention of SARS-CoV-2. 本发明涉及一种生物学方法产生的核酸序列，其包含SARS-CoV-2的两个或三个一级核酸序列部分和不超过三个二级核酸序列部分，其中二级核酸序列部分编码具有由ORF3a、ORF6、ORF7a或ORF8编码的SARS-CoV-2氨基酸序列功能的氨基酸序列。本发明还涉及用于产生本发明核酸的宿主细胞或试剂盒、编码本发明的核酸的载体和可通过表达本发明的核酸获得的产物，